The SWISS BIOTECH Pavilion presents 47 innovative Swiss biotech companies, start-ups and organizations under the roof of Switzerland. Check out this link to find out more about them: https://www.s-ge.com/de/exhibitors?k=&fair%5B%5D=1899
Switzerland is one of the best and most innovative locations for biotechnology in Europe. Local companies hold leading positions throughout many sectors and thus attract capital and researchers from all over the world. The basis for this success is a close-knit network between research and development, driven by renowned universities, highly specialized SMEs and strong multinational corporations. In addition to being an attractive place to live for international specialists, Switzerland also offers a modern infrastructure, a beneficial funding environment and access to a highly-qualified workforce.
In 2022, the Swiss biotech industry saw new records in terms of revenues recognized (CHF 6.8 billion in 2022 compared to CHF 6.7 billion in 2021) as well as in R&D investments (CHF 2.7 billion in 2022 compared to CHF 2.6 billion in 2021). In line with this, the number of FTEs working in Swiss R&D biotech companies increased to more than 19’100 FTEs (year-on-year increase by 7.2%), which is also a new record high. Not surprisingly, and especially in view of the challenging environment for raising funds in 2022, these new records in terms of growth and R&D investments came at the price of companies needing to reduce some of their liquidity reserves (on average by 21% in 2022).
Further information about:
The Swiss Biotech Sector: https://www.swissbiotech.org/listing/biotech-report-2023-swiss-biotech-2022-facts-figures/
Switzerland as a business location: www.s-ge.com/invest
Switzerland is one of the best and most innovative locations for biotechnology in Europe. Local companies hold leading positions throughout many sectors and thus attract capital and researchers from all over the world. The basis for this success is a close-knit network between research and development, driven by renowned universities, highly specialized SMEs and strong multinational corporations. In addition to being an attractive place to live for international specialists, Switzerland also offers a modern infrastructure, a beneficial funding environment and access to a highly-qualified workforce.
In 2022, the Swiss biotech industry saw new records in terms of revenues recognized (CHF 6.8 billion in 2022 compared to CHF 6.7 billion in 2021) as well as in R&D investments (CHF 2.7 billion in 2022 compared to CHF 2.6 billion in 2021). In line with this, the number of FTEs working in Swiss R&D biotech companies increased to more than 19’100 FTEs (year-on-year increase by 7.2%), which is also a new record high. Not surprisingly, and especially in view of the challenging environment for raising funds in 2022, these new records in terms of growth and R&D investments came at the price of companies needing to reduce some of their liquidity reserves (on average by 21% in 2022).
Further information about:
The Swiss Biotech Sector: https://www.swissbiotech.org/listing/biotech-report-2023-swiss-biotech-2022-facts-figures/
Switzerland as a business location: www.s-ge.com/invest
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
